BETHLEHEM, Pa., Oct. 7 /PRNewswire/ -- Particle Sciences announced today that it has sold T-COTE, its proprietary line of microfine titanium dioxide, to Sensient. With the sale, Sensient assumes all marketing and sales responsibilities and acquires the associated trademarks and existing business. Particle Sciences will remain involved during the transition for technical support. The sale does not result in any change to the product, its specifications or method and location of manufacture.
Particle Science's has been a pioneer in nanotechnology. Its staff invented, among other things, Z-COTE, microfine zinc oxide, a product that was sold to BASF in 1999. These pigments are primarily used as sunscreens. Particle Sciences also developed several surface treatments for these and other particles. "Particle Sciences has been at the cutting edge of fine particle technology for some time. We have a history of developing commercially successful products for ourselves and others," said Garry Gwozdz, Director of Formulation Services at the company.
The sale is in keeping with Particle Sciences growth plan as it focuses on its pharmaceutical development services. According to Dr. Robert Lee, VP Pharmaceutical Development, "Particle Sciences started, in 1991, as a topical formulation lab specializing in particulate API's. It has evolved into a leading provider of pharmaceutical development services ranging from preformulation to encapsulation to clinical trial material manufacturing. We remain expert in nano-delivery systems and provide a full suite of formulation and analytical services to our clients."
Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on emulsions, gels, particulates and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.
|SOURCE Particle Sciences|
Copyright©2008 PR Newswire.
All rights reserved